Premium
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma
Author(s) -
Joks Monika,
Jurczyszyn Artur,
Machaczka Maciej,
Skotnicki Aleksander B.,
Komarnicki Mieczysław
Publication year - 2015
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12412
Subject(s) - medicine , multiple myeloma , autologous stem cell transplantation , oncology , stem cell , transplantation , maintenance therapy , consolidation (business) , clinical trial , intensive care medicine , surgery , chemotherapy , biology , genetics , accounting , business
Novel agents including immunomodulatory drugs and proteasome inhibitors incorporated into induction regimens and subsequently followed by autologous stem cell transplantation in cases of multiple myeloma have resulted in enhancement of response rate and its depth. Maintaining or even improving the response is an important treatment goal. Most clinical trials have revealed increased progression‐free survival after consolidation and maintenance therapy. Some of them have also shown prolongation of overall survival. However, continuous therapy may be associated with significant side effects and costs, and therefore remains controversial. Treatment decisions should be individualized and based upon projected benefits and risks.